the initial supernatant (i.e., without the cell sediment/clot) at 4°C for 24 h (n ϭ 14).
Of late there has been a re-evaluation of therapeutic drug monitoring (TDM) strategies for optimizing cyclosporine (CsA) dosing in organ transplant recipients. Following the widespread introduction of the microemulsion formulation of CsA (Neoral ® ; Novartis Pharma), there has been a renewed interest in approaches to TDM that are based on the original observations of Lindholm and Kahan (1 ) . These authors demonstrated that total exposure to CsA, as reflected by the area under the concentration-time curve (AUC), was a better predictor of outcomes than predose (trough) CsA concentrations. Furthermore, several studies have shown that the AUC can be estimated with good reliability by means of a limited sampling strategy (2) (3) (4) .
Recently, clinical studies utilizing CsA measurements made at single or multiple time points in the early period (0 -6 h) after CsA ingestion have shown the potential of such measurements for improving clinical outcomes compared with the traditional, predose, approach (5-7 ). These studies have made recommendations for target CsA concentration ranges at either specific postdose time points (2 or 3 h) or for limited AUC measurements in the period 0 -6 h post dose. The recommendations were based on particular immunoassay methods and were for either kidney or liver transplant patients. We would like to raise two issues that may require further investigation before these new target CsA concentrations are adopted by other centers.
The first issue relates to the choice of analytical method used to measure CsA. Currently, there are six analytical techniques in common use for the measurement of CsA, and several more are in development (8, 9 ) . These analytical methods differ in their accuracy and specificity for the measurement of the parent CsA molecule in any one sample, and the average difference between two methods can be as much as 57%. This between-method difference itself is not constant and can be much larger, depending on such factors as transplant type, the time after transplantation, and liver function. Fig. 1 shows the mean values for the ratio between measurements of CsA made with immunoassays with a high specificity for the parent compound and HPLC. Although there is a trend for each immunoassay method to give a higher value relative to HPLC, this relative difference is not constant for two different pooled samples from kidney transplant patients; both pooled samples were prepared from samples that had been collected as predose (trough) samples. The variability between methods is less well documented for samples collected in the early period after CsA dosing. Thus, the application of target CsA concentration ranges based on a published study that used a radioimmunoassay to measure CsA in samples collected at, e.g., 2 h post dose, in a center that utilizes a fluorescence polarization immunoassay would need to be validated to document whether these between-method differences are larger or smaller at such time points.
The second issue relates to our concern about the possible lack of adherence to best-practice analytical guidelines for handling samples containing high CsA concentrations. A recent proficiency testing survey of 125 clinical laboratories that were challenged with a blood sample containing a high concentration of CsA (added drug concentration, 2000 g/L) produced a broad range of values (1082-3862 g/L) although the laboratories had been alerted to the approximate concentration of CsA in the sample before analysis (10 ) . This large variability was noted in a sample to which CsA had been added; the variability could be even greater in patient samples because CsA metabolites may not dilute in a linear fashion in immunoassays. In our opinion, the large variability in the analysis of high concentrations of CsA is, in part, attributable to a lack of on-site validated dilution guidelines. Blood samples containing high CsA concentrations, particularly those collected ϳ2 h after dosing, often require dilution before analysis because the CsA concentration in these samples may be higher than that of the highest CsA calibrator supplied with the assay. This is illustrated by the experience of two of us (R.G.M. and L.M.S.) for the measurement of CsA in samples collected 2 h post dose. For kidney transplant patients (R.G.M.), the median CsA concentration was 761 g/L, (range, 143-2300 g/L; n ϭ 56) with the Emit ® immunoassay (Dade Behring); for heart transplant patients (L.M.S.), the median CsA concentration was 1303 g/L (range, 720-2211 g/L; n ϭ 35) with a validated HPLC assay. It is worth noting that the highest calibrator supplied with the Emit assay is only 500 g/L. Thus, if the dilution step is not carried out using a validated procedure that has been shown to be linear across a wide range of concentrations, the resulting CsA concentration may be inaccurate. In turn, when applied to a TDM approach that is designed to estimate the absorbance profile, these values may introduce unacceptable inaccuracies into the estimate.
These issues need to be addressed further. The differ- ences between the results produced by the various immunoassay methods, which produce a variable bias compared with a selective technique, require careful scrutiny at sample time points other than the traditional predose (trough) measurement. As shown above, and from interlaboratory comparisons (11 ), there is ample evidence demonstrating differences between analytical techniques for trough CsA concentration measurements, but these differences need to be studied for samples collected in the period 1-6 h after ingestion of CsA. We will be investigating this issue more fully in a series of controlled studies to be performed in the near future.
In addition, we hope that the manufacturers of commercially available CsA analytical systems will respond to changes in CsA TDM practices. For this, they should address the need for an increase in the ranges of their assay calibrators, as well as ensuring that validated dilution protocols are available for their customers. In the differential evaluation of patients with high anion gap metabolic acidosis of unknown origin, lactate determinations are frequently performed. For patients who ingest ethylene glycol (present in antifreeze), the high anion gap metabolic acidosis is the result of the metabolism of ethylene glycol to glycolic acid (1, 2 ) .
Interference by Glycolic Acid in the Beckman
We encountered unusual lactate results, when measured on the Beckman LX 20 (Beckman Coulter), for two patients who had ingested ethylene glycol. Specifically, the lactate results were suppressed (i.e., no result) with an appended error message, "rate high". When these specimens were diluted threefold, measurable lactate values were obtained.
The Beckman lactate method is based on a lactate oxidase/peroxidase coupled reaction with endpoint determination. The lactate concentration is determined from the absorbance (A) measurement taken after reaction equilibrium has been established. To ensure an equilibrium steady state, a rate measurement is made during the expected steady-state portion of the measurement period. A reaction rate Ն10 mA/min would indicate a nonequilibrium reaction condition and would lead to suppressed results and a "rate high" error flag.
We suspected, based on their structural similarities, that glycolate reacted as a poor substrate for lactate oxidase, generating a reaction rate Ͼ10 mA/min during the expected steady-state portion of the lactate reaction and thus causing the "rate high" error flag. When measured by LX 20, glycolate concentrations up to 11.8 mmol/L produced an apparent lactate value up to 0.4 mmol/L, whereas glycolate concentrations Ն13.2 mmol/L produced a suppressed lactate result and a "rate high" flag (Table 1) . Specimens with a "rate high" flag indeed displayed reaction rates Ͼ10 mA/min. Fig. 1 depicts the reaction course for lactate, glycolic acid, and combined lactate/glycolic acid. The equilibrium state for lactate after 100 s and the nonequilibrium reaction rate for 
